Recent stock move and business snapshot

Butterfly Network (BFLY) stock has recently traded around $4.24, with performance data showing mixed short term moves alongside a stronger past 3 months and 1 year. This has drawn attention to its handheld ultrasound business model.

Recent trading has been volatile, with a 1 day share price return of 6.8% decline and a 7 day share price return of 11.5% decline. However, the 90 day share price return of 25.4% and 1 year total shareholder return of 86.8% suggest momentum has been building over a longer horizon as investors reassess Butterfly Network’s growth potential and risks.

If handheld ultrasound and healthcare AI interest you, it can be worth widening the lens and checking out 35 healthcare AI stocks

With Butterfly Network trading at $4.24 and the average analyst price target at $5.69, the stock sits at a discount. Given the strong recent returns already on the board, investors may question whether there is still a buying opportunity or whether potential future growth is already reflected in the price.

Most Popular Narrative: 135.6% Overvalued

According to the most followed narrative, Butterfly Network’s fair value of $1.80 sits well below the recent $4.24 share price, which sets up a clear valuation gap for investors to weigh.

In a nut shell, I saw Butterfly Network as a medical break through and bought a few hundred shares at a $1.55/shr. and the following news confirmed my reasoning of buying; On November 17, 2025, Butterfly Network’s subsidiary signed a five-year co-development and licensing agreement with Midjourney for exclusive access to its semiconductor-based ultrasound technology, securing a US$15 million upfront payment, US$10 million annual license fees, and further milestone and revenue-sharing potential.

Want to see how this perspective gets to a much lower fair value than today’s price, even while baking in solid revenue growth and a healthy profit margin assumption.

On this view, the current share price of $4.24 sits well above the narrative’s $1.80 fair value, implying investors are already paying a premium to the cash flow and profitability profile that underpin this scenario. Readers who anchor on this framework may treat recent share price strength as enthusiasm that has run ahead of the underlying valuation model rather than confirmation of it.

Result: Fair Value of $1.80 (OVERVALUED)

However, this view could be challenged if ultrasound-on-chip adoption, Compass AI uptake, or Butterfly Network’s current annual revenue of US$102.915 million materially lag expectations.

Next Steps

With mixed views on value and risk, it helps to go beyond the headline numbers and test the assumptions yourself while this story is still evolving. To weigh both sides of the argument and see what stands out most for you, start with these 2 key rewards and 3 important warning signs

Looking for more investment ideas?

If you stop with just one stock, you risk missing opportunities that match your goals more closely. Keep hunting for ideas that truly earn a spot on your shortlist.

• Target potential upside with companies that combine strong fundamentals and attractive pricing by scanning through the 51 high quality undervalued stocks.
• Focus on resilience by checking out the 72 resilient stocks with low risk scores if you want stocks where risk scores stay front and center.
• Hunt for potential future standouts hiding in plain sight by working through the screener containing 23 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.